Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
United Overseas Bank (UOB) strategists Quek Ser Leang and Lee Sue Ann describe USD/CHF as consolidating after failing to extend lower, with Monday’s session confined to a narrow range around 0.8310. Intraday, they expect further sideways trading between nearby support and resistance. On a 1–3 week view, they have shifted to a neutral stance, looking for the pair to hold within a broad 0.8245–0.8365 corridor, while longer‑term upside appears limited.
Dollar-Swiss consolidation in broad range
"24-HOUR VIEW: Yesterday, we expected USD to “edge lower to 0.8245.” We were incorrect, as USD traded within a range of 0.8275/0.8323. The current price movements are likely part of a range-trading phase. Today, we expect USD to trade between 0.8290 and 0.8335."
"1-3 WEEKS VIEW: We revised our USD view from positive to neutral last Friday (02 Oct, spot at 0.8310). We highlighted that USD “has likely entered a range-trading phase between 0.8245 and 0.8365.” After USD dropped to a low of 0.8245, we indicated yesterday that “while USD subsequently dropped below 0.8245 with a low of 0.8225, the decline was brief. There has been no increase in downward momentum, and we continue to expect USD to trade between 0.8245 and 0.8365 for now.” There is no change in our view."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
ECB’s Rehn: High long-term rates contributing to a slowdown in growth
Euro: Downside risks with 1.1100 in sight against US Dollar – ING
Swiss Franc weakens as US Dollar (USD) gains on escalating geopolitical conflicts
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Crypto prices
More
